2.95
Alaunos Therapeutics Inc stock is traded at $2.95, with a volume of 2.74M.
It is down -30.09% in the last 24 hours and up +97.99% over the past month.
Alaunos Therapeutics Inc is a clinical-stage cellular immuno-oncology company dedicated to the treatment of solid tumors through adoptive TCR-T cell therapy. It strikes cancer at its core by engineering cell therapies that target Neoantigens arising from genomic mutations.
See More
Previous Close:
$4.22
Open:
$4.42
24h Volume:
2.74M
Relative Volume:
6.23
Market Cap:
$4.72M
Revenue:
-
Net Income/Loss:
$-36.46M
P/E Ratio:
-1.2292
EPS:
-2.4
Net Cash Flow:
$-30.20M
1W Performance:
+102.05%
1M Performance:
+97.99%
6M Performance:
+12.17%
1Y Performance:
-83.43%
Alaunos Therapeutics Inc Stock (TCRT) Company Profile
Name
Alaunos Therapeutics Inc
Sector
Industry
Phone
(346) 355-4099
Address
2617 BISSONNET ST, HOUSTON
Compare TCRT with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
TCRT
Alaunos Therapeutics Inc
|
2.95 | 4.72M | 0 | -36.46M | -30.20M | -2.40 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
474.62 | 121.88B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
573.45 | 62.69B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
555.11 | 33.86B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
235.74 | 30.51B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
238.51 | 25.69B | 3.81B | -644.79M | -669.77M | -6.24 |
Alaunos Therapeutics Inc Stock (TCRT) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Oct-04-22 | Resumed | Wells Fargo | Overweight |
Alaunos Therapeutics Inc Stock (TCRT) Latest News
Alaunos Therapeutics And 2 Other Promising Penny Stocks To Watch - Yahoo Finance
Alaunos Therapeutics, Inc. (NASDAQ:TCRT) Short Interest Down 12.5% in March - Defense World
Alaunos Therapeutics (NASDAQ:TCRT) Shares Down 6.5% – Here’s What Happened - Defense World
Lantheus acquires radiopharma CDMO Evergreen for up to $1bn - Pharmaceutical Technology
Alaunos Therapeutics (NASDAQ:TCRT) Stock Price Up 4% – Should You Buy? - Defense World
Light Horse emerges with $62m and Novartis partnership worth up to $1bn - Pharmaceutical Technology
Alaunos Therapeutics (NASDAQ:TCRT) Stock Price Down 0.5% – Time to Sell? - Defense World
TCRT stock touches 52-week low at $1.92 amid market challenges - Investing.com
Novartis acquires Kate Therapeutics to advance gene therapies - Pharmaceutical Technology
Alaunos Therapeutics Inc (TCRT) Quarterly 10-Q Report - Quartzy
Ziopharm: Q3 Earnings Snapshot - The Washington Post
TCRT Stock Touches 52-Week Low at $1.96 Amid Market Challenges - Investing.com Nigeria
TCRT stock touches 52-week low at $2.06 amid market challenges - Investing.com
Intracranial Therapeutic Market Rewriting its Growth Cycle |Novartis AG, BioMarin, CORESTEM Inc., Alaunos Therapeutics, – IndiaPolitics.com - IndiaPolitics.com
After axing its sole clinical prospect last year, Alaunos cuts ties with Precigen - Fierce Biotech
Alaunos Therapeutics ends key agreement and updates on financial condition By Investing.com - Investing.com Australia
Alaunos Therapeutics Ends Licensing Deal, Reassesses Strategy - Yahoo Finance
Precigen reclaims rights after terminating license agreement - Investing.com India
Precigen Terminates License Agreement With Alaunos Therapeutics - MarketWatch
Alaunos Therapeutics ends key agreement and updates on financial condition - Investing.com
Genentech buys Regor’s CDK inhibitors in $850m deal - Clinical Trials Arena
AskBio and Belief BioMed partner to advance gene therapies - Pharmaceutical Technology
Gene Switch / Molecular Switch Market Set to Reach USD 1.44 Billion by 2031 with 9.9% CAGR - WhaTech
Gilead and Genesis partner to create novel therapies using AI - Pharmaceutical Technology
Navigator gains $100m in Series A funding for antibody therapeutics - Pharmaceutical Technology
VION Biosciences acquires Echelon Biosciences - Pharmaceutical Technology
Eli Lilly inaugurates R&D facility in Boston, US - Pharmaceutical Technology
Genentech and Sangamo to develop neurodegenerative disease therapies - Pharmaceutical Technology
Alaunos Therapeutics announces 1-for-10 reverse stock split - Investing.com
XyloCor taps SmartWise’s infusion device for gene therapy administration - Clinical Trials Arena
Turn Bio and HanAll to develop therapies for age-related conditions - Pharmaceutical Technology
Avenzo Therapeutics secures $150m to bolster oncology pipeline - Pharmaceutical Technology
Gilead concludes acquisition of CymaBay Therapeutics for $4.3bn - Pharmaceutical Technology
Why C.H. Robinson Shares Are Trading Lower By Over 12%? Here Are Other Stocks Moving In Thursday's Mid-Day Session - Markets Insider
Alaunos Therapeutics Announces 1-for-15 Reverse Stock Split - TipRanks
TScan Therapeutics Appoints Jason A. Amello as Chief Financial Officer - citybiz
Kyowa Kirin acquires Orchard Therapeutics for $477.6m - Pharmaceutical Technology
NAYA buys gene therapy company Florida Biotech for $20m - Clinical Trials Arena
Genentech signs nanoparticle deal worth up to $644m with GenEdit - Pharmaceutical Technology
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday - InvestorPlace
Avistone raises $140m to support drug research and development - Pharmaceutical Technology
BridGene and Galapagos partner for oncology drugs discovery - Pharmaceutical Technology
Novartis allies with Voyager to develop gene therapies in $1.3bn deal - Pharmaceutical Technology
Why Is Alaunos Therapeutics (TCRT) Stock Up 37% Today? - MSN
Why Lantheus Holdings Shares Are Trading Lower By Over 22%? Here Are Other Stocks Moving In Monday's Mid-Day Session - Markets Insider
Syncona to buy biotechnology company Freeline Therapeutics - Pharmaceutical Technology
Alaunos Therapeutics Announces Third Quarter 2023 Financial Results, Phase 1 Clinical Data and Continued Exploration of Strategic Alternatives - Yahoo Finance
Ascidian Therapeutics raises $40m to advance drug development - Pharmaceutical Technology
AstraZeneca and Cellectis partner to advance cell and gene therapies - Pharmaceutical Technology
How gene therapies can transform sickle cell disease treatment - Pharmaceutical Technology
Alaunos (TCRT) to Wind Down Sole Clinical Study, Stock Dips 65% - Nasdaq
Alaunos Therapeutics Inc Stock (TCRT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):